Licensing and royalty revenue — Contract with customer, liability

Moderna Licensing and royalty revenue — Contract with customer, liability decreased by 38.5% to $8M in Q4 2024 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryLiquidity

SignalHigher is better

VolatilityModerate

First reportedQ4 2023

Last reportedQ4 2024Feb 21, 2025

Rolls up toContract Liabilities

How to read this metric

A higher balance indicates a larger backlog of future revenue to be recognized as performance obligations are met over time.

Detailed definition

This metric represents the outstanding balance of deferred revenue or contract liabilities arising from licensing and ro...

Peer comparison

Comparable to 'deferred revenue' or 'contract liabilities' on the balance sheet for companies with multi-year licensing contracts.

Metric ID: mrna_segment_licensing_and_royalty_revenue_contract_with_customer_liability

Historical Data

4 periods

	Q4 '23	Q2 '24	Q3 '24	Q4 '24
Value	$0	$20M	$13M	$8M
QoQ Change	—	—	-35.0%	-38.5%

Range$0 – $20M

Current Streak2+ quarters decline

Similar Metrics at Other Companies

Neurocrine BiosciencesNBIX View metric

BiogenBIIB View metric

Natera, Inc.NTRA View metric

Estee Lauder Companies Inc.EL View metric

Rivian Automotive, Inc.RIVN View metric

Frequently Asked Questions

What is Moderna's licensing and royalty revenue — contract with customer, liability?: Moderna (MRNA) reported licensing and royalty revenue — contract with customer, liability of $8M in Q4 2024.
What does licensing and royalty revenue — contract with customer, liability mean?: The total amount of money received from partners for licensing that has not yet been recognized as revenue.